Disparities in care for patients with curable hepatocellular carcinoma

HPB

Volumn 17, Issue 9, 2015, Pages 747-752

  Hoehn, Richard S ^a   Hanseman, Dennis J ^a   Jernigan, Peter L ^a   Wima, Koffi ^a   Ertel, Audrey E ^a   Abbott, Daniel E ^a   Shah, Shimul A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ASIAN; CANCER STAGING; CANCER SURGERY; CAUCASIAN; CONFERENCE PAPER; EDUCATIONAL STATUS; FEMALE; HEALTH CARE DISPARITY; HEALTH INSURANCE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SOCIAL STATUS; SOCIOECONOMICS; AGED; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TRENDS; UNITED STATES;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 84939436198     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12427     Document Type: Conference Paper

References (23)

1. Mikhail S, Cosgrove D, Zeidan A,. (2014) Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther 14: 1205-1218.
2. Njei B, Rotman Y, Ditah I, Lim JK,. (2015) Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 61: 191-199.
3. Tan D, Yopp A, Beg MS, Gopal P, Singal AG,. (2013) Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 38: 703-712.
4. Devaki P, Wong RJ, Marupakula V, Nangia S, Nguyen L, Ditah IC, et al,. (2014) Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer 120: 1725-1732.
5. Zak Y, Rhoads KF, Visser BC,. (2011) Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg 146: 778-784.
6. Hyder O, Dodson RM, Nathan H, Herman JM, Cosgrove D, Kamel I, et al,. (2013) Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg 217: 896-906.
7. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF,. (2011) Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 117: 1019-1026.
8. Mohanty S, Bilimoria KY,. (2014) Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. J Surg Oncol 109: 629-630.
9. Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V, et al,. (2010) Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer 116: 1801-1809.
10. Robbins AS, Cox DD, Johnson LB, Ward EM,. (2011) Persistent disparities in liver transplantation for patients with hepatocellular carcinoma in the United States, 1998 through 2007. Cancer 117: 4531-4539.
11. Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, et al,. (2013) Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg 258: 1022-1027.
12. Wong RJ, Corley DA,. (2009) Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci 54: 2031-2039.
13. Nathan H, Schulick RD, Choti MA, Pawlik TM,. (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249: 799-805.
14. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW,. (2010) Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol 17: 3104-3111.
15. Jones DK, Singer PM, Ayanian JZ,. (2014) The changing landscape of Medicaid: practical and political considerations for expansion. JAMA 311: 1965-1966.
16. Nathan H, Segev DL, Bridges JF, Massie AB, Cameron AM, Hirose K, et al,. (2013) Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol 20: 448-456.
17. Parsons HM, Harlan LC, Stevens JL, Ullmann CD,. (2014) Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J 20: 97-104.
18. Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM, et al,. (2013) A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg 148: 769-777.
19. Lassig AA, Joseph AM, Lindgren BR, Fernandes P, Cooper S, Schotzko C, et al,. (2012) The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg 147: 1083-1092.
20. Khullar OV, Gillespie T, Nickleach DC, Liu Y, Higgins K, Ramalingam S, et al,. (2015) Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base. J Am Coll Surg 220: 156-168.e154
21. Bruix J, Sherman M, and American Association for the Study of Liver Diseases. (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
22. Hoehn RS, Wilson GC, Wima K, Hohmann SF, Midura EF, Woodle ES, et al,. (2014) Comparing living donor and deceased donor liver transplantation: a matched national analysis from 2007 to 2012. Liver Transpl 20: 1347-1355.
23. Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, et al,. (2014) The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer 120: 2114-2121.